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Abstract 
Background: Lipid-based nanosystems have great potential for transdermal drug delivery. In this study, nanostruc-
tured lipid carriers (NLCs) for short-acting alkaloids lappacontine (LA) and ranaconitine (RAN) isolated from Aconitum 
sinomontanum (AAS) at 69.47 and 9.16% (w/w) yields, respectively, were prepared to enhance percutaneous permea-
tion. Optimized NLC formulations were evaluated using uniform design experiments. Microstructure and in vitro/
in vivo transdermal delivery characteristics of AAS-loaded NLCs and solid lipid nanoparticles (SLNs) were compared. 
Cellular uptake of fluorescence-labeled nanoparticles was probed using laser scanning confocal microscopy and 
fluorescence-activated cell sorting. Nanoparticle integrity during transdermal delivery and effects on the skin surface 
were also investigated.
Results: NLC formulations were less cytotoxic than the AAS solution in HaCaT and CCC-ESF cells. Moreover, cou-
marin-6-labeled NLCs showed biocompatibility with HaCaT and CCC-ESF cells, and their cellular uptake was strongly 
affected by cholesterol and lipid rafts. Significantly greater cumulative amounts of NLC-associated LA and RAN than 
SLN-associated alkaloids penetrated the rat skin in vitro. In vivo microdialysis showed higher area under the concen-
tration–time curve (AUC)0–t for AAS-NLC-associated LA and RAN than for AAS-SLN-associated alkaloids.
Conclusions: NLC formulations could be good transdermal systems for increasing biocompatibility and decreasing 
cytotoxicity of AAS. AAS-NLCs showed higher percutaneous permeation than the other preparations. These findings 
suggest that NLCs could be promising transdermal delivery vehicles for AAS.
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Background
Aconitum sinomontanum (AS) belongs to the Ranun-
culaceae family and is used extensively as an analgesic 
and antirheumatic agent in traditional Chinese medi-
cine [1]. The pharmacological effects of AS are attributed 
to diterpenoid and norditerpenoid alkaloids, primar-
ily lappaconitine and ranaconitine [2]. Recently, total 
alkaloid extracts of A. sinomontanum (AAS) have been 
used as pain relievers for patients with cancer [3]. The 
major metabolic pathways of the main components of 
AAS in rat urine are hydroxylation, O-demethylation, 
N-deacetylation, and ester hydrolyzation [4]. However, 
the oral bioavailability of AAS is poor, and its main com-
ponents including lappaconitine and ranaconitine have 
a relatively short half-life. Therefore, they require long-
term oral administration. It was reported that lappaco-
nitine has certain toxicities and its oral 50% lethal doses 
(LD50) in mice and rats are 32.4 and 20  mg/kg, respec-
tively [5]. Besides, its certain safety factor (CSF) and 
standard safety margin (SSM) are 1.01 and 1.0% for per 
os, respectively, which indicates a narrow therapeutic 
range and low therapeutic index with oral administration 
[6]. Transdermal delivery is superior to oral administra-
tion as a route for AAS because it avoids the first-pass 
metabolism in the liver. In addition, this route reduces 
drug toxicity and adverse reactions by maintaining stable 
and lasting blood drug concentrations [7].
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Lipid-based nanosystems are novel colloidal nanocarri-
ers that are used for transdermal drug delivery [8]. Solid 
lipid nanoparticles (SLNs) and nanostructured lipid car-
riers (NLCs) are two types of lipid nanoparticles that 
have been shown to enhance transdermal permeation 
[9]. Compared with other transdermal vehicles such as 
creams, tinctures, emulsions, and liposomes lipid nano-
particles exhibit negligible skin irritation, higher stability, 
and more controlled release [10]. NLCs consist of a mix-
ture of solid and liquid lipids and represent the second-
generation of lipid nanoparticle-based drug vehicles [11]. 
NLCs have the beneficial properties of SLNs and over-
come their limitations including limited drug-loading 
capacity, drug leakage during storage, and risk of gelation 
[12, 13]. Furthermore, NLCs have been confirmed to pro-
duce efficient transdermal drug permeation [14].
In the current study, a range of AAS-NLCs was success-
fully prepared to optimize the vehicle formulation. The 
microstructure and in  vitro/in vivo transdermal delivery 
characteristics of AAS-loaded NLCs were investigated 
and compared with those of AAS-loaded SLNs. Laser 
scanning confocal microscopy (LSCM) and fluorescence-
activated cell sorting (FACS) were used to probe the cel-
lular uptake of fluorescence-labeled nanoparticles by 
human epidermal keratinocyte (HaCaT) and human 
embryonic skin fibroblast (CCC-ESF) cell lines. To elu-
cidate the transdermal delivery mechanism of NLCs, the 
integrity of the nanoparticles during transdermal delivery 
and their effects on the skin surface were also investigated.
Results and discussion
Preparation of AAS‑NLCs
The stirring rate (rpm), stirring time (min), homogeniza-
tion pressure (bar), homogenization cycle, and cooling 
temperature were evaluated to optimize the preparation 
of the AAS-NLCs. As shown in Figure 1, the particle size 
and polydispersity index (PDI) were reduced as the stir-
ring rate was slowed or the stirring time was lengthened. 
As the homogenization pressure increased, the particle 
size and PDI were reduced but subsequently increased 
if the pressure continued to increase. Moreover, particle 
size decreased as the number of homogenization cycles 
decreased. In addition, a small particle size and low PDI 
were produced by cooling the formulation to room tem-
perature in an ice bath. It was previously reported that 
the instability of the preparation system is caused by 
an increase in the kinetic energy of droplets due to the 
increase in homogenization pressure and number of 
homogenization cycles [15]. Therefore, the production 
parameters were set as follows: stirring rate, 5,000  rpm; 
stirring time, 10 min; homogenization pressure, 800 bar; 
cooling temperature, 0°C; and five homogenization cycles 
were performed.
The compositions of the NLC formulations are presented 
in Tables  1 and 2. A multiple linear regression equation 
was generated using a linear multiple stepwise regres-
sion analysis as follows: Y1  =  −13.663X2X3  +  408.072 
(R2  =  0.755, p  <  0.05); Y2  =  53.214X1X4  –  2,278.216X42   
+  57.246 (R2 =  0.952, p  <  0.01); Y3 =  2.812X1 +  45.071 
(R2 = 0.890, p < 0.01); Y4 = 75.962X4 − 0.584 (R2 = 0.952, 
p < 0.01); Y5 = 0.83X1X4 − 2.019X3X4 + 0.023 (R2 = 0.996, 
p < 0.01). Most of the R2 values were higher than 0.9 and 
the p values were less than 0.05, indicating that the good-
ness of fitting was fine and the significant effects were gen-
erated from the factors on the responses, respectively. A 
multi-grid algorithm was used to identify suitable factors 
required to produce a particle size of less than 200  nm. 
These were, an entrapment efficiency (EE) for LA and 
RAN greater than 80 and 70%, respectively, and drug load-
ing (DL) for LA and RAN greater than 4 and 0.2%, respec-
tively. In the optimal formulation, the concentration of 
lipids, concentration of surfactants, solid/liquid ratio, and 
drug/lipid ratio were 9%, 5.5%, 2.91, and 0.1, respectively.
Characterizations of AAS‑NLCs
The particle size and PDI are important characteristics 
of NLCs that influence the distribution of nanoparti-
cles [16]. AAS-NLCs and AAS-SLNs had PDI values of 
Figure 1 Effect of optimization of the process parameters of 
high-pressure homogenization method. On a particle size and b 
polydispersity index.
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0.082 ±  0.009 and 0.073 ±  0.006, respectively and nar-
row size distributions (160.5 ± 7.9 and 176.6 ± 19.6 nm 
for AAS-NLCs and AAS-SLNs, respectively). The ZP val-
ues of the AAS-NLCs and AAS-SLNs were −24.8 ± 1.6 
and −20.3  ±  2.1  mV, respectively, indicating good sta-
bility in these systems. In addition, the EE and DL of the 
NLC-associated LA were 82.18 ± 1.93 and 4.55 ± 0.52%, 
respectively while the EE and DL of NLC-associated RAN 
were 81.87 ± 1.52 and 0.36 ± 0.01%, respectively. The EE 
and DL of the SLN-associated LA were 77.48 ± 2.56 and 
3.61 ±  0.75%, respectively, and the EE and DL of SLN-
associated RAN were 74.81  ±  1.97 and 0.21  ±  0.01%, 
respectively.
The morphologies of the AAS-NLCs and AAS-SLNs 
were observed using transmission electron microscopy 
(TEM). As shown in Figure 2, most of the particles were 
spheroidal and uniform in size.
Differential scanning calorimetry (DSC) was performed 
to investigate the melting and crystallization behavior of 
the lipid molecules and drugs in the nanoparticle prepa-
rations [17]. As shown in Figure  3, the bulk drug had 
endothermic peaks at 208.6 and 269.0°C, the Precirol 
ATO 5 displayed a melting point of 61.1°C, and the cryo-
protectant (mannitol) exhibited an endothermic peak at 
159.3°C. The physical mixture heating curves exhibited 
three endothermic peaks that corresponded to the melt-
ing points of the three components. These included the 
reduced endothermic peak of the bulk drug at 269.0°C 
and the moving endothermic peak of Precirol ATO 5 at 
51.5°C. The results indicated that the enhanced dissolu-
tion of the partial bulk drug in the solid lipids as the tem-
perature rose led to changes in crystalline structure. All 
the endothermic peaks of AAS disappeared and the peak 
of Precirol ATO 5 was significantly shifted to the right in 
the AAS-NLC and AAS-SLN heating curves, indicating 
an increase in lattice defects in the AAS-NLC and AAS-
SLN preparations. The results suggest that the drug was 
Table 1 Compositions of NLC formulations used in the optimization experiments [U*7(74) uniform experimental design]
NLCs Factor A (X1) Factor B (X2) Factor C (X3) Factor D (X4) Drug content
Lipid (%) Surfactant (%) Solid/liquid (w/w) Drug/lipid (w/w) (%, w/v)
NLC1 2 4 1:1.5 1:30 0.07
NLC2 4 6 2:1 1:25 0.16
NLC3 6 8 1:2 1:20 0.30
NLC4 8 3 1.5:1 1:15 0.53
NLC5 10 5 1:3 1:10 1.00
NLC6 12 7 1:1 1:5 2.40
NLC7 14 9 3:1 1:35 0.40
Table 2 Results of  NLC formulation optimization experiment using a U*7(74) uniform experimental design 
(mean ± standard deviation, n = 3)
NLCs Response (Y1) Response (Y2) Response (Y3) Response (Y4) Response (Y5)
Size (nm) EE (LA, %) EE (RAN, %) DL (LA, %) DL (RAN, %)
NLC1 374.0 ± 25.7 54.70 ± 7.23 48.93 ± 5.63 0.78 ± 0.05 0.04 ± 0.01
NLC2 137.2 ± 11.3 66.82 ± 2.66 57.78 ± 1.97 1.33 ± 0.12 0.02 ± 0.01
NLC3 353.4 ± 28.5 66.07 ± 8.63 65.27 ± 9.73 2.14 ± 0.11 0.12 ± 0.02
NLC4 508.7 ± 68.7 81.45 ± 5.92 57.46 ± 3.24 6.67 ± 0.58 0.26 ± 0.02
NLC5 424.3 ± 41.2 88.25 ± 7.22 80.84 ± 8.45 8.89 ± 0.57 0.85 ± 0.02
NLC6 157.9 ± 20.3 93.14 ± 6.12 83.86 ± 7.23 13.58 ± 1.21 1.59 ± 0.09
NLC7 97.1 ± 11.2 71.31 ± 4.32 78.85 ± 6.11 1.91 ± 0.22 0.21 ± 0.02
Figure 2 TEM images. Representative images of AAS-NLCs and AAS-
SLNs (×80,000 magnification).
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homogeneously dispersed in the nanoparticles in a disor-
dered crystalline state.
X-ray diffraction (XRD) and DSC are complementary 
analytical methods used in the assessment of crystallinity 
and polymorphism [18]. Unlike the physical mixture (Fig-
ure 4D), the characteristic peaks of AAS (Figure 4A), pre-
cirol ATO 5 (Figure 4B), and mannitol (Figure 4C) in the 
XRD graph of the nanoparticles preparation (Figure 4E, 
F) were absent or reduced, confirming the formation of 
disordered structures in the inner cores of the NLC and 
SLN particles.
In vitro release
The cumulative release percentage profiles of LA 
and RAN from the AAS-NLCs, AAS-SLNs, and the 
mixture of AAS and blank NLCs are shown in Figure 5. 
The aqueous solubility of LA and RAN in the medium 
was 849.79 ±  36.95 and 582.06 ±  16.27  µg/mL, respec-
tively, and the sink condition was maintained during the 
release study. Both SLN and NLC dispersions signifi-
cantly enhanced the in  vitro AAS release for 72  h. The 
results showed the LA and RAN dispersion from SLNs 
was 94.6  ±  5.2 and 71.8  ±  1.9%, respectively and from 
the NLCs was 98.5 ± 4.1 and 79.3 ± 2.7%, respectively. In 
comparison, their physical mixtures showed LA and RAN 
from SLNs at 58.8 ± 0.7 and 39.2 ± 1.7%, respectively and 
from NLCs was 58.8 ± 6.9 and 40.0 ± 2.8%, respectively, 
under the same experimental conditions. This disparity is 
most likely due to the disordered crystalline state of the 
drug that exhibited higher solubilization and was selected 
for nanoparticle formation [9]. In addition, the total drug 
released from the NLC formulations was slightly greater 
than that released from the SLN formulations, which was 
likely caused by the imperfections in NLCs resulting from 
the incorporation of liquid lipids into solid lipids [19]. 
Furthermore, AAS-NLCs exhibited an initial fast release 
of 12.2 ± 0.7 and 17.2 ± 1.4% for LA and RAN, respec-
tively for 0.5 h, which was possibly due to the portion of 
AAS that was localized at the surface of the nanoparticles.
Cytotoxicity studies
Most lipid nanoparticles formed from glycerides or their 
derivatives are safe and well tolerated by organisms [20]. 
The in vitro cytotoxicity of AAS, AAS-SLNs, AAS-NLCs, 
and the empty vehicles (without AAS, defined as blank 
Figure 3 DSC curves. Representative DSC curves of A bulk drug, B 
Precirol ATO5, C cryoprotectant, D physical mixture, E AAS-NLCs, and 
F AAS-SLNs.
Figure 4 XRD spectra. Representative XRD of A bulk drug, B Precirol 
ATO5, C cryoprotectant, D physical mixture, E AAS-NLCs, and F AAS-
SLNs.
Figure 5 In vitro release profiles. Release of a LA and b RAN from 
AAS-NLCs, AAS-SLNs, the mixture of AAS and unloaded NLCs, and the 
mixture of AAS and unloaded SLNs (n = 3).
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NLCs and blank SLNs) was evaluated in HaCaT and 
CCC-ESF cells. As shown in Figure  6, blank NLCs and 
SLNs showed no serious cytotoxicity at the tested con-
centrations (cell survival rates were higher than 80%). The 
viability of HaCaT and CCC-ESF cells treated with vari-
ous concentrations of the formulations containing AAS 
was reduced dose-dependently, and both AAS-SLN and 
AAS-NLC formulations were significantly (p < 0.05) less 
cytotoxic than the AAS aqueous suspension (1,000  µg/
mL) was. These results may be due to the fact that the 
free drug in the AAS suspension was released and imme-
diately permeated the cells by passive diffusion while the 
nanoparticles had to be internalized via endocytosis or 
phagocytosis and released through the drug release pro-
cess. AAS loaded in the tested nanoparticles achieved a 
biocompatibility with skin cells that was superior to that 
of the AAS aqueous suspension.
Cellular uptake
As shown in Figure 7, HaCaT and CCC-ESF cells showed 
time-dependent uptake of C6-labeled NLCs and SLNs. 
Moreover, differences in the fluorescence intensity 
between the NLC- and SLN-treated cells at the same 
incubation time were not significant (p > 0.05). The sim-
ilar uptake of NLCs and SLNs in HaCaT and CCC-ESF 
cells suggests that the solid lipids in the NLCs and SLNs 
had a similar effect on their biocompatibility.
Endocytosis pathway
To further characterize the endocytosis pathways 
through which the NLCs deliver drugs, seven endocyto-
sis inhibitors were tested in HaCaT and CCC-ESF cells. 
These inhibitors included chlorpromazine (CPZ, cationic 
amphipathic molecule that inhibits clathrin disassem-
bly) [21], filipin III (FLP, inhibitor of caveolae-mediated 
endocytosis via combination with cholesterol) [22], gen-
istein (GNT, inhibitor of tyrosine kinases associated with 
caveolae-mediated endocytosis) [23], cytochalasin D 
(CCD, which disrupts actin filaments and inhibits actin 
polymerization) [24], amiloride (DMA, blocker of epi-
thelial Na+ channels that prevents non-specific macro-
pinocytosis) [25], sodium azide (NaN3, a metabolic 
inhibitor that restrains cellular energy metabolism) [26], 
and monensin sodium (MS, a Na+ ionophore that has 
been reported to cause a marked increase in intracellu-
lar Na+ concentration) [27]. As shown in Figure 8, CPZ, 
GNT, DMA, NaN3, and MS treatments did not signifi-
cantly affect the internalization of the C6-labeled NLCs 
in CCC-ESF cells. In contrast, FLP and CCD significantly 
inhibited the uptake of NLCs in comparison with the 
control treatment (p < 0.05) and the inhibitory effect of 
ELP was stronger than that of CCD was. This suggests 
that the uptake of C6-labeled NLCs into CCC-ESF cells 
was mainly mediated by caveolae-mediated endocytosis 
but macropinocytosis was also involved. In contrast, of 
the tested endocytosis inhibitors, only FLP significantly 
Figure 6 Cytotoxicity of alkaloids isolated from AAS solution, AAS-
SLNs, AAS-NLCs, unloaded SLNs and unloaded NLCs. a HaCaT cells 
and b CCC-ESF cells (n = 3).
Figure 7 Mean fluorescence intensity of cells treated with cou-
marin-6 (C6)-labeled NLCs or C6-labeled SLNs. Cells were treated 
for 15, 60, and 120 min and then measured using flow cytometry. a 
HaCaT and b CCC-ESF cells (n = 3).
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reduced the average fluorescence intensity of the HaCaT 
cells (p < 0.05), showing that caveolae-mediated endocy-
tosis was involved in the internalization of HaCaT cells. 
These results suggest that the internalization of the drug 
cargo of NLCs involved cholesterol and lipid rafts in the 
HaCaT and CCC-ESF cells.
Confocal imaging
The uptake of C6-labeled NLCs and SLNs by the 
HaCaT and CCC-ESF cells was visualized using LSCM 
(Figure  9). Hoechst-stained nuclei appeared blue and 
LysoTracker Red-labeled lysosomes appeared red. The 
colocalization of C6-labeled NLCs or SLNs (green) and 
LysoTracker (red) in the periphery of HaCaT and CCC-
ESF cells produced yellow fluorescence in the cytochyl-
ema. After incubation with C6-labeled nanoparticles, 
cells showed strong green and weak red fluorescence in 
the cytosol, which was probably caused by lysosomal 
escape of C6 from the NLCs, and the LysoTracker lost 
its fluorescence under neutral conditions in the cytosol 
[28]. These findings demonstrate that C6-labeled nano-
particles facilitate drug outflow from lysosomes, and 
that the fluorochrome is primarily distributed in the 
cytochylema.
In vitro permeation studies
The enhanced transdermal permeation of drugs pack-
aged in the lipid nanoparticles in comparison with other 
vehicles is mainly due to the increased surface area in 
which they interface with skin corneocytes, superior 
skin occlusion characteristics, and more effective hydra-
tion of the stratum corneum (SC) [29]. In our studies, 
the AAS-NLCs enhanced the transdermal penetration 
of LA and RAN (Figure  10) more effectively than the 
AAS-SLNs did. Initially, AAS was released rapidly from 
both SLNs and NLCs but showed sustained release 
afterward, which was consistent with the in vitro release 
study. Over the duration of the experiment, NLCs 
released cumulative amounts of LA and RAN that 
were greater than the amounts released by the SLNs. 
The enhanced drug release from the NLC formulations 
may be attributable to the greater drug encapsulation 
achieved with the NLC vehicle. In addition, labrasol, 
which was used in the NLCs, acts as a surfactant, which 
may loosen or fluidize the lipid bilayers of the SC [19].
Nanoparticle tracking analysis (NTA)
No fluorescent nanoparticles were found in the blank 
control sample (Figure  11a), demonstrating that flak-
ing skin particles did not influence the experimental 
outcome. The C6-labeled NLCs and SLNs were each 
diluted 1,000,000-fold and fluorescent nanoparticles 
were detected (Figure 11b, c). This ensured the sensitiv-
ity of the method for small quantities of nanoparticles 
such as those that might be transported across the skin. 
As shown in Figure 11d and e, fluorescent nanoparticles 
were not detected in the receptor fluid after permeation 
by C6-labeled NLCs or SLNs. It is also believed that rigid 
particles above 10 nm do not penetrate intact skin [30]. 
This finding is consistent with reports on lipid nanopar-
ticles, which are not considered to penetrate the SC [14].
Effect on SC structure
The surface of blank nude mouse skin (without any treat-
ment) was intact, smooth, and showed a tightly com-
pacted SC layer (Figure 12). However, the surface of skin 
exposed to the NLC or SLN formulations was jagged and 
the cracks in the SC were larger in size (Figure 12). The 
lipids and surfactants in the vehicles may erode the SC, 
and thereby disrupt its lipid arrangement. This disruptive 
effect on the SC may have been exacerbated by the occlu-
sive effect of the nanoscale lipid particles.
In vivo skin microdialysis
In the in vitro and in vivo RR validation studies, STD1–
STD6 were used as perfusates and a linear correlation 
was obtained between the drug concentrations in the per-
fusate and the dialysate (LA, [Cp–Cd] = 0.431Cp − 0.022, 
Figure 8 Effects of endocytosis inhibitors on cellular uptake. Effects 
of inhibitors in a HaCaT and b CCC-ESF cells (n = 3, *p < 0.05 vs. 
control group).
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r2  =  0.997 [in vitro]; [Cp–Cd]  =  0.345Cp  +  0.215, 
r2 =  0.991 [in vivo]; RAN, [Cp–Cd] =  0.418Cp +  0.394, 
r2  =  0.996 [in vitro]; [Cp–Cd]  =  0.318Cp  +  0.330, 
r2 = 0.987 [in vivo]). This correlation implied that in vitro 
and in vivo RR measurements obtained via retrodialysis 
are independent of perfusate concentrations, validating 
the feasibility of the microdialysis method to detect true 
unbound extracellular levels of LA and RAN.
In vivo time-concentration profiles of LA and RAN 
after topical application of the AAS-NLCs and AAS-
SLNs on the abdominal skin in rats are depicted in 
Figure 13, and results for some pharmacokinetic param-
eters are summarized in Table 3. The peak concentration 
(Cmax) of the AAS-NLC and AAS-SLN formulations were 
similar at approximately 8  h after administration. The 
drug concentrations at the sites where NLCs or SLNs 
were applied first increased and then decreased, which 
implied similar patterns of transdermal drug absorption 
for both lipid nanoparticle formulations. Their occlusive 
effects and ability to hydrate the SC [31] enhance the 
transdermal drug permeation achieved by NLCs and 
SLNs. Drug absorption may be enhanced by the for-
mation of a lipid membrane that fuses with the SC and 
allows the drug to diffuse into the skin. Moreover, drug 
molecules must be released from nanoparticles before 
they can be absorbed, which may cause drug levels in the 
skin to fluctuate. The higher Cmax values (LA and RAN, 
207.45  ±  29.89 and 46.60  ±  9.56  ng/mL, respectively) 
were obtained with AAS-NLCs, and the area under the 
concentration–time curve (AUC0–t) of LA and RAN was 
3.27- and 4.42-fold higher, respectively than that of AAS-
SLNs (Table  3). Altering skin physiology and modifying 
NLC formulations to influence drug partitioning and 
solubility are potential strategies to enhance transdermal 
drug penetration. The addition of labrasol as a liquid lipid 
increased the drug-loading capacity of NLCs and fluid-
ized the lipid bilayers of the SC, which may enhance the 
permeation effect compared with that of the SLNs [19].
Figure 9 LSCM images. Representative LSCM images of a HaCaT cells after incubation with C6-labeled SLNs, b HaCaT cells after incubation with 
C6-labeled NLCs, c CCC-ESF cells after incubation with C6-labeled SLNs, and d CCC-ESF cells after incubation with C6-labeled NLCs.
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Conclusion
In this study, AAS-NLCs were successfully prepared 
with the following components in optimal propor-
tions: Precirol ATO5, labrasol, Cremophor RH40, and 
AAS (6.7, 2.3, 5.5, and 0.9%, w/v, respectively). The 
NLCs strongly affected cholesterol and lipid rafts in 
the cellular pathway. These results show that the NLCs 
achieved transdermal delivery of AAS that was supe-
rior to that produced by SLNs, suggesting that NLCs 




LA and RAN (purity >98%, each) were purchased 
from Shaanxi Chenguang Pharmaceutical Co., Ltd. 
(Xi’an, China). AS was purchased from Shaanxi Min-
sheng Medicine Co., Ltd. (Xi’an, China). Caprylo-
caproyl macrogol-8 glycerides (Labrasol®) and glyceryl 
palmitostearate (Precirol® ATO 5) were provided by 
Gattefossé (Montesquieu, France). Polyoxyl cas-
tor oil (Cremophor® RH40) was obtained from BASF 
(Ludwigshafen, Germany). High-glucose Dulbecco’s 
modified Eagle medium (DMEM-high) was obtained 
from Thermo Fisher Scientific (Waltham, MA, USA). 
Trypsin (0.25%), 0.02% ethylenediaminetetraacetic 
acid (EDTA), fetal calf serum (FCS), 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 
and phosphate-buffered saline (PBS) were obtained 
from Shanghai Usen Biotechnology (Shanghai, 
China). Filipin III, genistein, cytochalasin D, 5-(N,N-
dimethyl)-amiloride hydrochloride, monensin sodium, 
Lyso-Tracker® Red DND-99, and Hoechst33258 stain 
were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA). Sodium azide was obtained 
from Beijing Bei-na Kai-chuang Biotech Co., Ltd 
Figure 10 In vitro skin-permeation profiles. Representative profiles of a LA and b RAN from AAS-NLCs and AAS-SLNs (n = 3).
Figure 11 NanoSight image of test formulations. Representative 
images of a blank control, b C6-labeled NLCs and c C6-labeled SLNs 
diluted 1,000,000-fold, d a sample treated with C6-labeled NLCs, and 
e a sample treated with C6-labeled SLNs.
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(Beijing, China), and chlorpromazine hydrochloride 
was obtained from Aladdin Industrial Inc. (Shanghai, 
China). All other chemicals were obtained from Sinop-
harm Chemical Reagent (Shanghai, China) and were of 
high-performance liquid chromatography (HPLC) or 
analytical grade.
Animals and cell lines
Male Sprague–Dawley rats and nude mice weighing 
200  ±  20 and 25  ±  5  g, respectively were used in this 
study, which was conducted with the approval of the 
Animal Ethical Committee of the Shanghai University of 
Traditional Chinese Medicine (permit SYXK [Hu] 2009-
0069). All the animals were acclimatized at a temperature 
of 25 ± 2°C and relative humidity of 70 ± 5% for 1 week 
with food and water provided ad  libitum. The HaCaT 
cell line was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA), and the CCC-
ESF cell line was obtained from the Chinese Academy of 
Medical Sciences (Beijing, China).
Figure 12 Microstructures of nude mouse skin. Skin samples with normal control (blank), AAS-NLCs-treated (NLC), and AAS-SLNs-treated (SLN) 
obtained via SEM (×400,000 magnification).
Figure 13 Time course of rat skin penetration by test alkaloids. a LA and b RAN concentrations sampled after the administration of AAS-NLCs and 
AAS-SLNs on the abdominal skin of rats over a period of 10 h (n = 5).
Table 3 Pharmacokinetic parameters of LA and RAN released from AAS-NLCs and AAS-SLNs in rat dermis measured using 
in vivo microdialysis
Mean ± SD, n = 5, * p < 0.05 vs. AAS-SLNs.
Parameter AAS‑NLCs AAS‑SLNs
LA RAN LA RAN
Tmax (h) 7.70 ± 0.84 8.00 ± 0.50 7.70 ± 0.45 7.50 ± 0.00
Cmax (ng/mL) 207.45 ± 29.89* 46.60 ± 9.56* 65.93 ± 6.37 10.07 ± 1.93
MRT0–t (h) 6.04 ± 0.03 6.24 ± 0.07 6.11 ± 0.05 6.04 ± 0.07
AUC0–t (ng/mL × h) 1,239.07 ± 176.39* 248.44 ± 50.85* 378.72 ± 56.04 56.16 ± 8.89
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HPLC analysis
LA and RAN were analyzed using an Agilent 
HPLC system (HP 1260, Agilent Technologies, Inc., 
Santa Clara, USA) with an octadecylsilyl column 
(Inspire™ C18 (Dikma Technologies, Beijing, China), 
250  mm ×  4.6  mm, 5  µm). The mobile phase consisted 
of a solution of methanol and 0.01 mol L−1 monosodium 
phosphate aqueous solution (80:20, v/v) at a flow rate of 
1.0 mL min−1. The column temperature was maintained 
at 30°C and the detector was set at 252  nm. Quantified 
samples were filtered through a 0.45-µm filter membrane 
before automatic injection into the HPLC system.
Preparation of AAS
AAS was extracted using alcohol reflux extraction meth-
ods. Briefly, powdered AS was soaked in acidified water 
(pH 1)/90% ethanol (v/v) at a ratio of 1:10 (w/v), and then 
extracted by reflux with heating for 2 h in a water bath at 
100°C. The extract was collected, and then replaced with 
fresh solvent. This extraction procedure was repeated 
twice. After filtration and alkalization (pH  >  10) with 
ammonium hydroxide, the extracts were further treated 
with chloroform and concentrated by vacuum distilla-
tion. To prepare the AAS, the residue was dissolved in 
acetone and recrystallized with diethyl ether, and the 
obtained extracts were vacuum-dried (relative vacuum, 
−0.1 MPa; temperature: 60°C) for 12 h. The main com-
ponents of AAS, which have superior pharmacologi-
cal effects were LA and RAN (yield, LA 69.47 and RAN 
9.16%, w/w, respectively).
Ultra‑performance liquid chromatography (UPLC)‑tandem 
mass spectrometry (MS/MS) analysis
The in  vivo dialysate samples were analyzed using a 
Thermo Ultimate 3000 ultra-performance liquid chro-
matography system coupled to a Thermo TSQ Quan-
tum triple-quadrupole tandem mass spectrometer 
(Thermo Finnigan, San Jose, CA, USA) equipped with 
an electrospray ionization source. The Xcalibur 1.2 data 
analysis system was used. Chromatographic separa-
tion was achieved on an octadecylsilyl column [Hyper-
sil GOLD™ C18 (Thermo Finnigan, San Jose, CA, USA), 
100 mm × 2.1 mm, 5 µm] maintained at 30°C. The mobile 
phase consisted of methanol:water:acetic acid (70:30:0.2, 
v/v/v) with a flow rate of 0.2 mL/min, and the injection 
volume was 5 µL. The mass spectrometer was oper-
ated in the positive mode. The spray voltage was set to 
3,500 kV and the capillary temperature was set at 350°C. 
Nitrogen was used as the sheath (35 psi) and auxiliary gas 
(10 psi). The precursor-to-production transitions were 
monitored at m/z 585 → 356 for LA and m/z 601 → 422 
for RAN using the selected reaction monitoring mode. 
Quantified samples were extracted with diethyl ether and 
dissolved in methanol before automatic injection into the 
UPLC-MS/MS.
Preparation of AAS‑NLCs
The different AAS-NLC formulations were prepared 
using the hot-melt high-pressure homogenization 
method [32] with Precirol ATO 5, labrasol, and Cremo-
phor RH40 as the solid lipid, liquid lipid, and surfactant, 
respectively. Briefly, AAS was dissolved in the solid (Pre-
cirol ATO 5) and liquid (labrasol) lipids, which were 
melted in a water bath at 75°C. The required amount of 
the aqueous phase (Cremophor RH40 in double-distilled 
water) was then added to the oleic phase dropwise under 
high-speed mixing using a disperser (Ultra Turrax T25, 
IKA, Staufen, Germany). The resulting pre-emulsion 
was then immediately passed through a high-pressure 
homogenizer (NS1001 L, GEA, Parma, Italy). To opti-
mize the NLC formulations, a uniform design with a 
U*7(74) table was used in this study that included the 
following factors: the amount of lipids (solid and liquid 
lipids, factor A), the amount of surfactant (factor B), the 
ratio of solid lipids to liquid lipids (factor C), and the 
ratio of drugs to lipids (factor D). This scheme produced 
seven NLC formulations (NLC1–NLC7) that were char-
acterized with regards to particle size, EE, and drug DL. 
The AAS-SLN preparations used for comparison were 
prepared using the same method with Precirol ATO5 
(9.0%, w/v), Cremophor RH40 (5.5%, w/v), and the same 
drug content.
Characterization of AAS‑NLCs
Particle size and zeta potential (ZP)
A computerized Malvern Autosizer Nano ZS90 inspection 
system (Malvern Instruments, Malvern, UK) was used to 
measure the average particle size and zeta potential (ZP) 
of each preparation via dynamic light scattering. The sam-
ples were diluted with distilled water before measurements 
were taken and each was performed in triplicate.
EE and DL
The free drug was separated using an ultrafiltration 
method [33]. Centrifugal filter tubes (10 kDa, Pall Corpo-
ration, Port Washington, NY, USA) were used to estimate 
the EE and DL. Nanoparticle suspensions (0.5 mL) were 
placed in the centrifugal filter tubes, and centrifuged for 
15 min at 5,000 rpm. The free drug was separated from 
the drug entrapped in the nanoparticles and collected at 
the bottom of the tube through the membrane. The sepa-
rated and total drug contents were evaluated using a vali-
dated HPLC. The total drug content in each preparation 
was calculated after extraction with acetonitrile in an 
ultrasonic bath. The EE and DL were calculated using the 
following equations:
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where, Wtotal, Wfree, and Wlipids are the total amount of LA 
and RAN in the preparation, the amount of untrapped 
LA and RAN, and the amount of lipids used in the for-
mulation, respectively.
Tem
The physical appearance of the AAS-NLCs were exam-
ined and with that of the AAS-SLNs using TEM (JEM-
1230; Jeol, Ltd., Tokyo, Japan). The samples were 
prepared for negative staining as follows. The samples 
were diluted with distilled water and placed on a film-
coated copper grid (Zhong Jing Ke Yi Technology Inc., 
Beijing, China) to dry for about 20  min. Next, a drop 
of 2% phosphotungstic acid was added to the film and 
allowed to dry for 10  min, after which the sample was 
examined under the TEM.
Dsc
DSC was performed using a differential scanning calo-
rimeter (Shimadzu DSC-60; Shimadzu Corporation, 
Kyoto, Japan). The sample (lyophilized in advance using 
mannitol 10%, w/v as the cryoprotectant) was heated at 
the scanning rate of 10°C per min over a temperature 
range of 30–300°C. An empty aluminum pan was used as 
a reference for comparison.
Xrd
XRD analysis of the AAS-loaded lipid nanoparticles (lyo-
philized in advance using mannitol 10%, w/v as the cryo-
protectant) was performed using an X-ray diffractometer 
(Rigaku Corporation, Tokyo, Japan) to assess their crys-
talline structures. The X-ray diffraction patterns were 
recorded at 2θ values of 3–50° at a scanning speed of 5° 
per min using a Cu-Kα radiation source.
In vitro release
The dialysis method was used to assess the in vitro drug 
release pattern [34]. Dialysis bags (molecular weight 
cutoff, 14 kDa, Pall Corporation, Port Washington, NY, 
USA) containing 5  mL of the test formulations were 
firmly tied and immersed in 100  mL of normal saline 
containing 20% polyethylene glycol 400 (PEG 400, v/v) 
at 37  ±  0.5°C and stirred at 120  rpm with a paddle. 
At each sampling time point, 1  mL of the sample was 
withdrawn, and then replaced with the same volume 
of fresh medium. The withdrawn samples were meas-












In vitro cell uptake
Cell culture
HaCaT and CCC-ESF were grown in fresh culture 
medium (DMEM-high) containing 10% FCS (v/v) and 
maintained at 37°C under humidified conditions with 
5% CO2 (Forma 3111, Thermo Fisher Scientific). For the 
subculture, cells growing as a monolayer were detached 
from the culture dish with 0.05% (w/v) trypsin solution. 
All cell-handling procedures were performed on a super-
clean bench (VCM-620; Dabao Instrument, Suzhou, 
China) and aseptic techniques were employed.
Cytotoxicity
The cytotoxicity of free drugs, AAS-NLCs, AAS-SLNs, 
and empty vehicles was determined using the MTT assay 
[35]. The AAS solution was prepared using dimethylsul-
foxide solution and culture medium (DMEM-high) while 
the AAS-NLC preparations, AAS-SLN preparations, 
and empty vehicle suspension were prepared in culture 
medium (DMEM-high) over a range of 50–1,000  µg/
mL. The working solutions at various concentrations 
were added to cells cultured in 96-well microplates at 
5 × 103 cells/well and incubated for 4 h. Then, the culture 
fluid was replaced with fresh DMEM (no FBS) contain-
ing 500 μg/mL MTT. After a 4-h incubation at 37°C, the 
culture medium was removed and replaced with 200 μL 
dimethylsulfoxide. The plate was shaken for 10 min in the 
dark and the absorbance was determined at 570 nm in a 
microplate reader (Biotek Synergy HT, Gene Company 
Limited, Hong Kong, China). All measurements were 
performed in triplicate and results were calculated as a 
percentage of the values obtained from the control wells 
(untreated cells).
Cellular uptake
Cellular uptake was evaluated using flow cytometry with 
coumarin-6 (C6) dehydrated alcohol solution (1.0  mg/
mL) instead of AAS. NLC and the compared SLN for-
mulations containing 10 µg/mL C6 were prepared. Cells 
were incubated with the C6-labeled formulations in the 
culture dish for 15, 60, and 120  min, after which the 
culture medium was removed and the cells were rinsed 
thrice with 1 mL PBS (pH 7.4). After trypsinization, the 
cells were carefully collected into 5-mL BD tubes (Fal-
con 352002; Becton, Dickinson and Company, Franklin 
Lakes, NJ, USA) and centrifuged at 1,500  rpm at 25°C 
in a refrigerated centrifuge (Thermo Fisher Scientific, 
Waltham, MA, USA). The supernatant was removed and 
the cells were resuspended in 0.5 mL of PBS (pH 7.4, con-
taining 1% FCS, v/v) in the BD tubes. A total of 20,000 
cells were analyzed using a flow cytometer (FCM, Bec-
ton, Dickinson and Company, Franklin Lakes, NJ, USA). 
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Cells that had not been incubated with any fluorophore 
served as the blank control cells.
Endocytic pathway
Endocytosis mechanisms were assessed using cellular 
uptake assays in the presence of chemicals known to 
inhibit specific endocytosis pathways [36]. Cells were 
incubated with CPZ, FLP, GNT, CCD, DMA, NaN3, or 
MS (at 10, 5, 54, 1.52, 2.66, and 2.08 µg/mL, respectively) 
for 30  min at 37°C. After exposure to these inhibitors, 
200 µL of C6-labeled NLCs was added to each well and 
incubated for 30  min. After the incubation, cells were 
prepared for flow cytometry as described earlier and 
the data for at least 20,000 cells were acquired. The cells 
treated with C6-labeled NLCs alone were considered as 
the control cells.
Confocal imaging
First, 100  µL of the culture medium (no FCS) in glass-
bottom culture dishes (MatTek P35G-0-10-C35  mm, 
MatTek Corporation, Ashland, USA) was removed and 
replaced with an equal volume of either the C6-labeled 
NLC suspension or the C6-labeled SLN suspension. 
After a 30-min incubation in 5% CO2 atmosphere main-
tained at 37°C, the culture fluid was removed, and the 
culture dish was washed thrice with 1  mL pre-cooled 
PBS (pH 7.4). Fresh DMEM (no FBS) containing 50 nM 
LysoTracker Red was added to each sample and the cells 
were incubated for 30  min at 37°C. Hoechst 33342 was 
added to a final concentration of 10 μg/mL and the cells 
were cultured for a further 5  min at 37°C. The culture 
fluid was removed rapidly, 1 mL of aqueous paraformal-
dehyde solution (4%, w/v) was added to the culture dish 
to fix the cells for 15 min, the fixative was removed, and 
then the cells were washed thrice with 1  mL PBS (pH 
7.4). The cells were optically scanned within 2 h at differ-
ent increments through the z-axis with a TCS SP5 confo-
cal imager (Leica Microsystems, Wetzlar, Germany).
In vitro transdermal studies
Rats were anesthetized, euthanized, their abdominal fur 
was removed with a razor, and then the skin was excised 
carefully and washed with normal saline. In vitro per-
meation experiments were conducted using a Franz dif-
fusion cell (Fulansi Electronic Science and Trade Co, Ltd, 
Tianjin, China) fitted with excised rat skin [37]. Each 
donor compartment had a diffusion area of 2.0 cm2 and 
each receptor compartment was filled with 12.5  mL of 
freshly prepared normal saline containing 20% PEG 400 
(v/v) to provide sink conditions [38]. The saline in the 
receptor compartment was maintained at a temperature 
of 37 ±  0.5°C and stirred at 500  rpm using a magnetic 
bar. One mL of each formulation was added to the donor 
compartment, and it was sealed with parafilm. At prede-
termined time points, 1 mL of the sample was removed 
from the receptor compartment, and replaced with an 
equal volume of receptor fluid equilibrated to 37 ± 0.5°C. 
The permeation studies were performed in triplicate and 
the collected samples were analyzed using HPLC.
In vitro fluorescence detection‑based NTA in receptor fluid
A Franz diffusion cell fitted with excised rat skin was pre-
pared as described earlier. The receptor compartment 
was filled with purified water containing 0.02% NaN3 
and the donor compartment was filled with 1.0 mL of the 
C6-labeled NLC suspension, C6-labeled SLN suspension, 
or 1.0 mL of C6 suspended in distilled water as a blank 
control sample. The diffusion cell was stirred at 500 rpm 
while the temperature was maintained at 37  ±  0.5°C. 
After 12  h, samples were removed from each receptor 
compartment and measured using a NanoSight NS300 
system (Malvern Instruments, Malvern, UK), which was 
equipped with a scientific sCMOS camera, a 405  nm 
laser with temperature control, and a 503 nm long-pass 
filter for fluorescent particle analysis. NanoSight NS300 
NTA 3.0 software was used for the data collection and 
the temperature was maintained at 25°C throughout the 
experiment.
Effect on SC structure
A nude mouse was anesthetized and immobilized on a 
mat with the abdomen facing upward, and then the skin 
in this region was divided into three areas. A flat cylin-
drical plastic cover with an area of 1  cm2 that served 
as a drug pool was glued above each skin area using 
cyanoacrylate adhesive. One mL of NLCs or SLNs was 
applied to the plastic cover, and the untreated skin area 
was maintained as a control region. After 8 h, the mouse 
was euthanized, and the abdominal skin was collected 
and washed with normal saline. The skin samples were 
fixed in glutaraldehyde for 24 h, rinsed with PBS (pH 7.4), 
fixed in 1% osmic acid, dehydrated with ethanol, and then 
dried using CO2 critical point drying. Finally, the skin 
was sputtered with platinum and evaluated using a scan-
ning electron microscope (SEM, Quanta FEG250, FEI, 
Hillsboro, OR, USA).
Microdialysis system
The microdialysis system used was composed of a WZ-
50C6 microinfusion pump (Smiths Medical, St. Paul, MN, 
USA) with a 20-mL plastic syringe and a linear microdi-
alysis probe. The regenerated cellulose (inner diameter, 
200  µm; outer diameter, 280  µm; molecular weight cut-
off, 13 kDa) was used to prepare Spectra/Por® microdialy-
sis hollow fibers (Spectrum Laboratories, Inc., Houston, 
TX, USA). The linear microdialysis probes were made 
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by gluing the fibers to the quartz capillary tubing (Welch 
Materials, Inc., Shanghai, China) using cyanoacrylate 
adhesive (Mxbon® Super Glue, Cartell Chemical Co., Ltd., 
Chia-Yi Hsien, Taiwan). The inlet tubes of the probes were 
connected to the microinjection pump using polyethylene 
tubing [39]. In all experiments, the length of the mem-
brane accessible to dialysis was 20 mm, and the perfusate 
flow rate was 0.2 mL/h. Cannulas were used as insertion 
guides and vials were used to collect the dialysate samples.
Standard (STD) solutions of LA and RAN were pre-
pared by dissolving pure LA and RAN in normal saline 
containing 20% PEG400 (v/v). The concentrations of the 
STD solutions (STD1–STD6) were 1, 5, 10, 25, 50, and 
100 ng/mL, respectively.
In vivo recovery validation in vivo correction
Before the microdialysis studies, in vitro recovery was esti-
mated to ensure that the probes would provide reproduc-
ible and efficient sampling. The dialysis membrane portion 
of the linear probe was completely submerged in a stand-
ard solution of LA or RAN (STD, prepared by dissolving 
pure LA or RAN in 20% PEG 400 in normal saline, v/v) at 
37°C in a 50-mL beaker. The probe was perfused with 20% 
PEG 400 in normal saline (v/v) at a flow rate of 0.2 mL/h. 
After an equilibration period of 30 min, the dialysate was 
collected in a small vial for 30 min and dialysate samples 
were analyzed using UPLC-MS/MS. Relative recovery 
(RRd) was calculated as the slope of the linear regression of 
the drug concentration in the dialysate (Cd) as a function 
of the drug concentration in the medium (Cm):
For the retrodialysis studies, the probe was perfused with 
STD solutions (Cp) and the medium was replaced with 
20% PEG 400 in normal saline (v/v). The drug concentra-
tion in the dialysate (Cd) was determined, and RRrd was 
calculated by the following equation:
In vivo RR was estimated using the retrodialysis-by-drug 
method. A linear probe was inserted into the dermis of the 
abdominal skin of a rat anesthetized with intraperitoneal 
urethane aqueous solution (1.3 g/kg). The rat was perfused 
with 20% PEG 400 in normal saline (v/v) for 1 h, followed 
by an equilibration period of 30 min using the STD solu-
tion as the perfusate. After a further 30 min of STD per-
fusion, dialysate samples were collected. UPLC-MS/MS 
assays were conducted to determine the diffusive loss of 
the drug indirectly, and RR was calculated using Eq. (4).
In vivo microdialysis studies
To determine the concentration of the administered 
drug, a probe was inserted into the dermis of the 






abdominal skin of a rat anesthetized with intraperito-
neal urethane aqueous solution (1.3 g/kg), and the active 
dialysis window was placed below the site of topical drug 
administration. The rat was immobilized on a mat with 
the abdomen facing upward and the fur in this region 
was manually shaven, taking care not to damage the 
skin. The ambient temperature was maintained at 25°C. 
For the in  vivo microdialysis sampling following probe 
implantation, the connective tubing from the probe was 
secured to the skin with adhesive tape to fix its position. 
The probe was continuously perfused with 20% PEG 400 
in normal saline (v/v) at a flow rate of 0.2 mL/h. The skin 
was allowed to equilibrate for 1 h before a blank sample 
was taken, and 1  mL of AAS-NLCs or AAS-SLNs was 
applied 1.5 h after the start of perfusion. A flat cylindri-
cal plastic cover of about 1  cm in height and 1.5  cm in 
diameter, with an edge width of 2 mm was glued above 
the application site using cyanoacrylate adhesive, and 
the drug was applied to the cover the skin just above the 
probe. During the experiment, the application site, and 
the probe were kept at the same level. Dialysate samples 
were collected in small vials, which were replaced every 
30 min. Dialysis sampling was performed for 10 h.
Statistical analysis
Results are presented as mean ± standard deviation (SD). 
Differences were analyzed using the Student’s t test with 
statistical program for the social sciences (SPSS) software 
version 19.0 (IBM Corp., Armonk, NY, USA). P values 
<0.05 were considered to be statistically significant. The 
uniform design with a U*7(74) table was optimized using 
the SPSS software and VB software version 6.0 (Micro-
soft Corp., Redmond, WA, USA). The cutaneous phar-
macokinetic parameters of LA and RAN were calculated 
using noncompartmental analysis with the DAS 2.0 soft-
ware (Mathematical Pharmacology Professional Com-
mittee of China, Shanghai, China).
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